Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CD73 Inhibitor
CD73-IN-11 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP into adenosine. By inhibiting CD73, this compound disrupts adenosine production, which is known to induce immunosuppressive effects and can promote tumor proliferation and metastasis. CD73-IN-11 is an essential tool for studying tumor-related diseases and investigating the role of adenosine in cancer biology. -
CD73 Inhibitor
CD73-IN-2 is a potent inhibitor of CD73, demonstrating an IC50 value of 0.09 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the regulation of extracellular adenosine levels. CD73-IN-2 is valuable for research applications focused on immuno-oncology, inflammation, and metabolic diseases. -
CD73 Inhibitor
CD73-IN-19 is a potent CD73 inhibitor, exhibiting a 44% inhibition of CD73 enzymatic activity at 100 μM. It effectively counteracts TCR-induced blockade of T cell proliferation at concentrations of 10 μM and 100 μM, highlighting its role in modulating immune responses. Additionally, CD73-IN-19 has been shown to inhibit hA2A receptor activity in HEK-293 cells, with a Ki value of 3.31 μM. This compound demonstrates potential value in studies related to immune disorders and therapeutic interventions. -
CD73 Inhibitor
CD73-IN-10 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. By inhibiting CD73, this compound can reduce the immunosuppressive effects of adenosine, which play a role in tumor proliferation and metastasis. CD73-IN-10 is valuable for research applications focused on tumor biology and the study of tumor-related diseases. -
CD73 Inhibitor
CD73-IN-13 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool in the investigation of tumor-related diseases, offering insights into the biochemical pathways associated with cancer progression. Researchers can utilize CD73-IN-13 to explore the therapeutic potential of targeting CD73 in various malignancies. -
CD73 Inhibitor
CD73-IN-8 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP to adenosine. Elevated levels of adenosine are associated with immunosuppression and enhanced tumor growth and metastasis. CD73-IN-8 is valuable for investigating tumor-related diseases and exploring therapeutic strategies aimed at modulating the adenosine pathway in cancer research. -
CD73 Inhibitor
CD73-IN-14 is a potent and selective inhibitor of CD73, exhibiting an IC50 of 0.17 nM. This compound enhances the recruitment of tumor-infiltrating CD8+ T cells and demonstrates significant anti-tumor activity. Additionally, CD73-IN-14 features an alkyne group that enables its use in click chemistry applications, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing partners. This reagent is valuable for studies in immuno-oncology and chemical biology, allowing for the exploration of immune modulation and therapeutic strategies. -
CD73 Inhibitor
ZM522 is a potent CD73 inhibitor with an IC50 value of 0.56 μM. This compound enhances immune activity by elevating interferon-γ (INF-γ) levels and modulating T cell activation. ZM522 is suitable for research applications in immunology and cancer therapy, offering potential insights into immune response mechanisms and therapeutic strategies. -
CD73 Inhibitor
MethADP trisodium is a potent inhibitor of CD73, targeting the enzymatic conversion of ATP to adenosine. This compound plays a crucial role in studies investigating the ATP-adenosine signaling pathway and its implications in cancer, immunology, and inflammatory diseases. MethADP trisodium is instrumental for researchers exploring the modulation of adenosine levels and the effects on immune cell function. -
CD73 Inhibitor
MRS4620 is a potent inhibitor of CD73, exhibiting an inhibitory constant (Ki) of 0.436 nM. This compound is primarily utilized in cancer immunology research, where it can help elucidate the role of CD73 in immune regulation and tumor microenvironment modulation. MRS4620 is valuable for studies aimed at enhancing anti-tumor immunity and understanding the mechanisms of immune evasion in cancer. -
CD73 Inhibitor
CD73-IN-9 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Elevated adenosine levels are associated with immunosuppressive effects and can promote tumor proliferation and metastasis. This compound is valuable for investigating tumor-related diseases and understanding the role of CD73 in cancer biology. -
OTUD4/CD73 Inhibitor
ST80 is an inhibitor of the OTUD4/CD73 interaction. It effectively decreases the protein level of CD73 and enhances its turnover, which reduces the immune evasion capabilities of tumor cells. This results in significant antitumor efficacy, particularly in the context of immunosuppressive triple-negative breast cancer (TNBC), making ST80 valuable for research in cancer immunotherapy. -
CD73 Inhibitor
PSB-0963 is a selective and competitive inhibitor of ecto-5'-nucleotidase (eN or CD73), exhibiting an inhibition constant (Ki) of 150 nM for rat ecto-5'-nucleotidase. This compound demonstrates high selectivity for eN/CD73 over other ectonucleotidases, such as NTPDases 1-3, and P2Y receptors. PSB-0963 is valuable for research involving cancer biology, particularly in studies focused on immune regulation and tumor microenvironment interactions. -
CD73 Inhibitor
CD73-IN-12 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool for investigating tumor-related diseases and their underlying mechanisms. Additionally, CD73-IN-12 features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it useful for click chemistry applications in biochemical research. -
CD73 Inhibitor
CD73-IN-18 is a potent inhibitor of extracellular 5-nucleotidase (CD73). By blocking CD73 activity, this compound has shown potential in anti-cancer research, enhancing immune responses against tumors. It serves as a valuable tool in studies aimed at understanding tumor microenvironments and developing novel cancer therapies. -
CD73 Inhibitor
CD73-IN-6 is a potent inhibitor of CD73, a key enzyme involved in the adenosine pathway. This compound is essential for investigating the role of CD73 in cancer biology and its potential therapeutic applications. CD73-IN-6 can be utilized in research focused on tumor immunology and the modulation of the tumor microenvironment, providing insights into cancer progression and treatment strategies. -
CD73 Inhibitor
CD73-IN-7 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Adenosine plays a critical role in immunosuppression and can facilitate tumor proliferation and metastasis. CD73-IN-7 is suitable for research applications focused on tumor biology and the modulation of immune responses in cancer. -
CD73 Inhibitor
MethADP disodium is a specific inhibitor of CD73, an enzyme involved in the regulation of adenosine signaling. By inhibiting CD73 activity, MethADP disodium can impede the production of adenosine, which plays a critical role in immune suppression and tumor progression. This compound is useful for research applications focusing on cancer immunotherapy, inflammation, and metabolic diseases, providing insights into the modulation of the adenosine pathway. -
COX Inhibitor
Inulicin (1-O-Acetylbritannilactone) is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 activity. This compound demonstrates significant biological activity by inhibiting lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) as well as the expression of COX-2. Additionally, Inulicin suppresses NF-κB activation and its translocation, making it valuable for research applications related to inflammation and cancer. -
COX Inhibitor
COX-1-IN-3 is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting non-steroidal anti-inflammatory properties. This compound is valuable for research focused on inflammation and pain management, as it modulates the biosynthesis of prostaglandins. Its specificity for COX-1 makes it an important tool for studying COX-1-related pathways and associated biological processes. -
COX Inhibitor
(S)-Ketorolac is a nonsteroidal anti-inflammatory drug that primarily functions as an inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. This compound is characterized by its potent analgesic and anti-inflammatory properties, making it suitable for pain management in various research applications. Its ability to selectively inhibit COX enzymes positions (S)-Ketorolac as a valuable tool in studies focused on inflammatory processes and pain modulation. -
COX Inhibitor
(±)-Naproxen is a non-steroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 enzymes, exhibiting IC50 values of 8.72 μM and 5.15 μM, respectively. This compound is primarily used in research for its potent anti-inflammatory and analgesic properties. It provides valuable insights into the mechanisms of pain relief and inflammation, making it suitable for various studies in pharmacology and biochemistry. -
sEH/COX-1 Inhibitor
PTUPB is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.9 nM and 1.26 μM, respectively. This compound is relevant for studies investigating the modulation of inflammatory processes, as it effectively interferes with pathways involving arachidonic acid metabolism. PTUPB serves as a valuable research tool for exploring the therapeutic potential of sEH and COX-1 inhibition in various disease models. -
COX/5-LOX Inhibitor
Phenethyl ferulate is a potent inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), displaying IC50 values of 4.35 μM and 5.75 μM, respectively. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammation-related pathways. Its ability to modulate these key enzymes positions it as a promising candidate for studies focused on inflammatory diseases and therapeutic interventions. -
COX Inhibitor
4-Methylamino antipyrine is a COX inhibitor derived from the active metabolite of Metamizole, a pyrazolone non-steroidal anti-inflammatory drug (NSAID). It exhibits analgesic and antipyretic activities, making it beneficial for alleviating pain and reducing fever. Although its anti-inflammatory properties are relatively weak, 4-Methylamino antipyrine serves as a valuable tool in pharmacological studies involving pain management and inflammatory responses. -
COX-2/iNOS Inhibitor
α-Chaconine is an inhibitor of COX-2 and iNOS, which demonstrates significant anti-inflammatory activity. It effectively reduces the transcriptional expression of COX-2, IL-1β, IL-6, and TNF-α. Additionally, α-Chaconine suppresses LPS-induced expression of iNOS and COX-2 at both the protein and mRNA levels, along with their promoter activities in RAW 264.7 macrophages. This makes α-Chaconine a valuable reagent for studies focused on inflammation and related signaling pathways. -
COX Inhibitor
Sphondin is a cyclooxygenase (COX) inhibitor that effectively reduces the levels of COX-2 protein and prostaglandin E2 (PGE2) release in A549 cells stimulated by IL-1β. This compound's anti-inflammatory properties make it a valuable tool for research into COX-related pathways and the modulation of inflammatory responses in various cellular models. Sphondin can facilitate investigations into therapeutic strategies for inflammatory diseases. -
5-LOX/COX Inhibitor
FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), exhibiting IC50 values of 3.5 μM and 3.1 μM, respectively, in RBL-1 cells. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its dual inhibition of leukotriene and prostaglandin synthesis positions FPL 62064 as a pertinent reagent for studies focusing on inflammation and related therapeutic interventions. -
sPLA2/COX-2 Inhibitor
Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that functions as an inhibitor of secretory phospholipase A2 (sPLA2) and cyclooxygenase-2 (COX-2). This compound exhibits potent anti-inflammatory activity, making it useful in research focused on inflammation and pain modulation. Its dual mechanism of action presents opportunities for investigating pathways involved in inflammatory diseases and related therapeutic interventions. -
COX Inhibitor
Pelubiprofen is an orally active anti-inflammatory agent that inhibits cyclooxygenase (COX) enzyme activity, displaying IC50 values of 10.66 μM for COX-1 and 2.88 μM for COX-2. It demonstrates notable anti-inflammatory and analgesic properties, making it valuable for research in pain management and inflammation pathways. Pelubiprofen can be utilized in studies examining the roles of COX enzymes in various biological processes and diseases. -
COX Inhibitor
Ketorolac-d5 is a deuterated form of Ketorolac, a non-steroidal anti-inflammatory drug that functions as a nonselective inhibitor of cyclooxygenase (COX). It displays inhibitory potency with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is widely utilized in pharmacological studies to investigate the biochemical pathways of pain and inflammation, as well as in drug metabolism and pharmacokinetic research. -
COX-2 Inhibitor
EXP3179 is a selective cyclooxygenase-2 (COX-2) inhibitor, notably an intermediate aldehyde metabolite of Losartan. It effectively reduces the expression of COX-2 in endothelial cells, leading to significant anti-inflammatory effects. This compound is useful in research applications focused on inflammation and related signaling pathways. -
ERAP1 Inhibitor
ERAP1 modulator-2 is a potent inhibitor of the enzyme ERAP1, exhibiting an IC50 value of less than 100 nM. This compound effectively modulates the activity of ERAP1, influencing peptide trimming and presentation in the context of antigen processing. It is valuable for research applications focused on immune regulation, inflammation, and the modulation of major histocompatibility complex (MHC) class I-mediated responses. -
Anti-inflammatory Agent, Aminopeptidase Inhibitor
2-(2'-Pyridyl)benzimidazole is an effective anti-inflammatory agent and a potent inhibitor of methionine aminopeptidase in Escherichia coli. This compound exhibits tridentate ligand properties, capable of forming stable complexes with various transition metal ions. Its applications extend to biochemical research focused on inflammatory processes and amino acid metabolism, making it a valuable reagent for studies in these areas. -
Keap1/Nrf2 Inhibitor
PRL-295 is an orally active inhibitor targeting the interaction between Keap1 and Nrf2. By enhancing the thermal stability of Keap1, PRL-295 disrupts its binding to Nrf2, leading to the activation of Nrf2-dependent genes such as NAD(P)H:quinone oxidoreductase 1 (NQO1). This compound has demonstrated protective effects against Acetaminophen-induced liver injury in murine models, making it a valuable tool for research into oxidative stress and related pathologies. -
MALT1 Protease Inhibitor
Safimaltib is a potent and selective allosteric inhibitor of MALT1 protease. It exhibits significant biological activity by hindering MALT1's function, which may contribute to tumor stasis in various cancer models. This compound is valuable for research applications exploring the role of MALT1 in oncogenesis and potential therapeutic interventions in malignancies driven by aberrant MALT1 activity. -
MALT1 Inhibitor
MLT-985 is a selective allosteric inhibitor of MALT1, demonstrating an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and intervenes in aberrant signaling associated with the CARD11/BCL10/MALT1 complex. MLT-985 is applicable in research focused on cancer, particularly in the study of B cell malignancies. -
MALT1 Protease Inhibitor
MLT-943 is a selective and orally active inhibitor of MALT1 protease. It effectively inhibits stimulated IL-2 secretion in peripheral blood mononuclear cells (PBMC) and whole blood, demonstrating consistent IC50 values across species (0.07-0.09 μM in PBMC and 0.6-0.8 μM in whole blood). With its notable anti-inflammatory properties, MLT-943 is a valuable reagent for investigating FcγR-mediated inflammatory processes. -
MALT1 Inhibitor
Z-VRPR-FMK is an irreversible inhibitor of the MALT1 protein. It effectively inhibits the growth and invasion of diffuse large B-cell lymphoma by blocking MALT1-induced NF-κB activation and matrix metalloproteinase (MMP) expression. This makes Z-VRPR-FMK a valuable tool for research investigating the role of MALT1 in oncogenesis and therapeutic strategies targeting NF-κB pathways. -
MALT1 Inhibitor
MLT-231 is a potent allosteric inhibitor of MALT1, demonstrating high selectivity with an IC50 of 9 nM. This compound effectively prevents the cleavage of endogenous BCL10, with an IC50 of 160 nM. MLT-231 shows promising antitumor activity in mouse models of activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), making it a valuable tool for research into therapeutic strategies targeting MALT1-related pathways. -
MALT1 Inhibitor
MALT1-IN-11 is a potent MALT1 protease inhibitor with an IC50 of less than 10 nM. This compound effectively inhibits interleukin-10 (IL-10) secretion, with an IC50 range of 10-100 nM. MALT1-IN-11 is utilized in research focused on cancer, autoimmune diseases, and inflammatory disorders, providing valuable insights into the role of MALT1 in these pathological conditions. -
MALT1 Protease Inhibitor
MALT1-IN-9 is a selective MALT1 protease inhibitor, demonstrating an IC50 of less than 500 nM in Raji MALT1-GloSensor cells. This compound exhibits significant anticancer activity, making it a valuable tool for research focused on targeting MALT1 in various oncological studies. Its efficacy supports investigations into the role of MALT1 in cancer progression and therapeutic development. -
MALT1 Inhibitor
MALT1-IN-5 is a potent inhibitor of the MALT1 protease, targeting the NF-κB signaling pathway. This compound has demonstrated significant biological activity in disrupting MALT1-dependent signaling processes. MALT1-IN-5 is primarily utilized in cancer research to investigate the role of MALT1 in tumorigenesis and its potential as a therapeutic target. -
MALT1 Protease Inhibitor
(R)-MALT1-IN-7 is a selective MALT1 protease inhibitor, designed for investigating the role of MALT1 in various biological processes. It exhibits potent inhibitory activity, making it valuable for cancer research, particularly in studies exploring the underlying mechanisms of tumorigenesis and potential therapeutic interventions. This compound serves as a useful tool in elucidating the function of MALT1 in both normal and pathological cellular contexts. -
MALT1 Inhibitor
MALT1-IN-3 is a selective MALT1 protease inhibitor with a potent IC50 of 0.06 μM. This compound demonstrates inhibitive effects on human IL-6 and IL-10 production in OCI-LY3 cells, exhibiting IC50 values of 0.14 μM and 0.13 μM, respectively. MALT1-IN-3 is valuable for research into gene expression regulation, immune response modulation, and potential therapeutic strategies in various malignancies. -
MALT1 Inhibitor
(R)-MLT-985 is a selective allosteric inhibitor of MALT1, exhibiting an IC50 value of 3 nM. This compound effectively suppresses cell proliferation and disrupts aberrant signaling initiated by the CARD11/BCL10/MALT1 complex. (R)-MLT-985 is primarily utilized in research related to cancer, particularly in the study of B cell malignancies. -
MALT1 Inhibitor
NVS-MALT1 is an allosteric inhibitor of the MALT1 protein, disrupting its activity and providing a valuable tool for studying MALT1-mediated signaling pathways. This compound demonstrates the ability to modulate NF-κB activation and enhance apoptosis in cancer cells, making it relevant for research in oncology and immune response. It is particularly useful in investigations focusing on B-cell lymphoma and other MALT1-associated diseases. -
MALT1 Inhibitor
Ocipumaltib is a potent inhibitor of mucosa-associated lymphoid tissue protein 1 (MALT1), which plays a crucial role in various signaling pathways. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Additionally, Ocipumaltib is applicable in the study of infection, neurological disorders, and hematological diseases, providing insights into MALT1's involvement in these conditions. -
MALT1 Inhibitor
(S)-MALT1-IN-5 is a potent inhibitor targeting the MALT1 protease. This compound effectively inhibits MALT1 activity, which may provide therapeutic insights for conditions associated with aberrant T cell receptor and B cell receptor signaling, as well as cancers and inflammatory diseases linked to MALT1 dysregulation. (S)-MALT1-IN-5 is a valuable tool for researching MALT1-related disease mechanisms and developing potential interventions. -
MALT1 Inhibitor
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is a potent inhibitor of MALT1, a key protein involved in various signaling pathways. This compound effectively inhibits cell proliferation and migration, demonstrating significant anticancer activity. It is valuable for research applications focused on cancer biology and therapeutic strategies targeting MALT1-related pathways.
